Will the US FDA grant full approval for a novel therapy that halts or significantly reverses the progression of Alzheimer’s disease before the end of 2028?

Alzheimer's: Halting Progression by 2028?

While recent therapies have shown marginal success in slowing cognitive decline in the very early stages of Alzheimer's, no treatment has been approved that definitively halts or reverses the disease's progression. This prediction sets a high bar, requiring a drug or therapy that meets the FDA's strict standards for 'full approval' (not accelerated/conditional) for a truly transformative outcome.

The Complexity of the Brain

The slight 'No' majority reflects the enormous complexity of Alzheimer's and the long failure rate of drugs targeting various mechanisms (amyloid, tau, etc.). While the funding and research intensity are immense, the average time from Phase 1 clinical trial to full approval is close to 10 years, making a definitive, reversing breakthrough by 2028 an ambitious, but not impossible, scientific stretch goal.